Results 81 to 90 of about 864,749 (292)

Nanovesicles With Mechanically Induced Adjuvanticity for Robust Melanoma Vaccination Toward Tumor‐Associated Macrophages

open access: yesAdvanced Science, EarlyView.
Rigidity‐tunable nanovesicle (P‐Pm) with mechanically induced adjuvanticity toward tumor‐associated macrophages (TAMs) was designed to engineer R848/gp100 antigen ‐loaded nanovaccine (P@Rg‐Pm), which achieved outstanding anti‐tumor outcomes in both therapeutic and preventive model of B16‐F10 melanoma.
Bangyue Luo, Liyan Qiu
wiley   +1 more source

HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy

open access: yesHuman Vaccines & Immunotherapeutics, 2017
HPV16 persistent infection is a well-known condition that precedes human cancer development. High risk HPV E5 proteins cooperate with E6/E7 oncogenes to promote hyper-proliferation of infected cells leading to possible cancer progression.
Francesca Paolini   +8 more
doaj   +1 more source

Creating Markets for New Vaccines Part II: Design Issues [PDF]

open access: yes
Several programs have been proposed to improve incentives for research on vaccines for malaria, tuberculosis, and HIV, and to help increase accessibility of vaccines once they are developed.
Michael Kremer
core  

mRNA Vaccines against Flaviviruses

open access: yes, 2021
Numerous vaccines have now been developed using the mRNA platform. In this approach, mRNA coding for a viral antigen is in vitro synthesized and injected into the host leading to exogenous protein expression and robust immune responses.
Clayton J. Wollner, Justin M. Richner
core   +1 more source

BCG HSP70 Reprograms Macrophages via Central Trained Immunity to Suppress Prostate Cancer

open access: yesAdvanced Science, EarlyView.
BCG‐derived HSP70 (Dnak) safely induces central trained immunity via epigenetic, metabolic, and O‐GlcNAcylation reprogramming of bone marrow progenitors, driving tumor‐associated macrophages toward an M1‐like phenotype to suppress prostate cancer. ABSTRACT Trained immunity offers a promising yet clinically challenging strategy for cancer immunotherapy,
Peng Liu   +12 more
wiley   +1 more source

A Marker-Free Bordetella bronchiseptica aroA/bscN Double Deleted Mutant Confers Protection against Lethal Challenge

open access: yesVaccines, 2019
Bordetella bronchiseptica is a leading cause of swine respiratory disorders which depict a great threat to well-flourished porcine industry. Vaccination remains an effective way for the prevention of B.
Weicheng Ai   +9 more
doaj   +1 more source

Evaluation of Hematological Profiles and Monocyte Subpopulations in Water Buffalo Calves after Immunization with Two Different IBR Marker Vaccines and Subsequent Infection with Bubaline alphaherpesvirus-1. [PDF]

open access: yesVaccines (Basel), 2023
Grandoni F   +13 more
europepmc   +1 more source

Acknowledgement to Reviewers of Vaccines in 2017

open access: yes, 2018
Peer review is an essential part in the publication process, ensuring that Vaccines maintains high quality standards for its published papers.[...
Vaccines Editorial Office
core   +1 more source

Developments in Rabies Vaccines: The Path Traversed from Pasteur to the Modern Era of Immunization

open access: yes, 2023
Rabies is a disease of antiquity and has a history spanning millennia ever since the first interactions between humans and dogs. The alarming fatalities caused by this disease have triggered rabies prevention strategies since the first century BC.
Anthony R. Fooks   +5 more
core   +1 more source

Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis

open access: yesAdvanced Science, EarlyView.
Engineered macrophages programmed in situ by LNP‐delivered IL‐6/4 fusion and LL37 mRNAs simultaneously dampen cytokine storm, promote M2‐like repair, and enhance direct bacterial killing in sepsis. This combinatorial strategy restores T cell and macrophage function, lowers organ bacterial burden, and improves survival, highlighting a precision, host ...
Tianyang Jie   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy